Latest Patents

Patents imply intellectual property and it has a $ value that can be associated depending on the field and type of patent that is allocated. Patents also increase the enterprise value of the company and help prevent copy-cats from copying the idea without having royalt payments or licencing deals. We like it when companies get patents awarded!. To protect IP companies aggressively file provisional patents even before they have a working product. The below table provides a way to look at what has been done by companies and use this as a factor to make investment decisions.

     
Title Filing Date Publication Date Grant Date
b7-h4-targeted antibody-drug conjugates, and methods of use thereof 2023-7-31 2023-8-09
Peptide-containing linkers for antibody-drug conjugates 2023-2-13 2023-4-25
Antibody drug conjugates comprising sting agonists 2022-12-27 2023-5-19
Monoclonal antibodies against her2 epitope and methods of use thereof 2022-10-26 2023-8-24
Napi2b-targeted polymer antibody-drug conjugate for the treatment of ovarian … 2022-9-09 2023-3-16
Protein-polymer-drug conjugates 2022-7-14 2023-6-15
NaPi2B-TARGETED POLYMER ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF 2022-6-28 2022-10-20
Site specific antibody-drug conjugates with peptide-containing linkers 2022-6-27 2022-8-01
Combination therapy of carboplatin and napi2b-targeted polymer antibody-drug … 2022-5-03 2022-11-10
Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] … 2022-1-30 2022-3-01
B7-H4 DIRECTED ANTIBODY AND DRUG CONJUGATES, AND METHODS OF USE THEREOF 2022-1-04 2023-4-12
Cysteine engineered antibody-drug conjugates with peptide-containing linkers 2021-4-19 2021-6-30
ANTIBODY-DRUG CONJUGATES COMPRISING STING AGONISTS 2021-4-05 2022-7-06
Antibody drug conjugates comprising sting agonists 2021-4-02 2022-10-28
Napi2b-targeted antibody-drug conjugates and methods of use thereof 2021-1-20 2021-9-30
SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS 2021-1-08 2022-9-07
Methods and nucleic acid molecules for cell-free and vector-free in vitro RNA … 2021-1-05 2022-7-08
Methods and nucleic acid molecules for cell-free and vector-free in vitro RNA … 2021-1-05 2022-7-08
Cell-free and vector-free in vitro RNA transcription methods and nucleic acid … 2021-1-05 2022-7-08
Dimeric compounds as sting agonists 2020-12-04 2023-3-09
Protein-Polymer-Drug Conjugate 2020-10-28 2021-3-04
STING AGONIST COMPOUNDS, AND METHODS OF USE 2020-7-31 2021-12-29
Compositions and methods for predicting response to napi2b-targeted therapy 2020-3-12 2020-4-30
Protein-polymer-drug conjugates 2020-1-23 2021-4-15
Pyrrolobenzodiazepine antibody conjugates 2018-12-21 2020-10-28
Pyrrolobenzodiazepine antibody conjugates 2018-11-27 2020-10-07
Pyrrolobenzodiazepines and conjugates thereof 2018-11-06 2020-5-26 2020-5-26
Methods of producing drug-loaded polymer scaffolds and protein-polymer-drug … 2018-6-22 2020-6-19
Combination therapies of her2-targeted antibody-drug conjugates 2018-2-27 2018-9-07
Peptide-containing linkers for antibody-drug conjugates 2017-11-22 2022-11-25
Protein-polymer-drug conjugates 2017-11-16 2018-5-24
Tubulysin compounds and conjugates thereof 2017-9-15 2018-8-30
Pyrrolobenzodiazepines and conjugates thereof 2017-6-22 2022-11-02 2022-11-02
ANTIBODY-DRUG CONJUGATES ADDRESSED TO NaPi2b AND ITS METHODS 2017-3-15 2018-11-14
Terminally modified polymers and conjugates thereof 2016-9-08 2017-5-04
Protein-polymer-drug conjugates -- 2016-3-18 2016-8-19
Monoclonal antibodies against her2 epitope and methods of use thereof 2015-6-18 2022-3-15
MONOCLONAL ANTIBODIES AGAINST HER2 EPITHOPE AND ITS METHODS OF USE 2015-6-18 2017-4-20
MONOCLONAL ANTIBODIES AGAINST THE HER2 EPITHOPE AND ITS METHODS OF USE 2015-6-18 2016-11-16
Protein-polymer-drug conjugates and methods of using same 2015-6-18 2015-12-24
Hydroxy-polmer-drug-protein conjugates 2013-12-12 2014-6-19
Auristatin compounds and conjugates thereof 2013-12-10 2015-11-05
Pharmaceutical Formulations of Biodegradable Biocompatible Camptothecin-Polymer … 2013-6-18 2014-1-02
Biocompatible biodegradable fumagillin analog conjugates 2013-2-15 2013-6-20
Modified Polymers for Delivery of Polynucleotides, Method of Manufacture, and … 2013-1-07 2013-5-02
PHARMACEUTICAL FORMULATIONS FOR CONJUGATES OF FUMAGILINE AND PHF DERIVATIVES 2012-12-26 2014-9-03
Pharmaceutical formulations for fumagillin derivative-phf conjugates 2012-12-21 2014-10-29
Protein-polymer-drug conjugates 2012-6-11 2013-12-12
Polyal drug conjugates comprising variable rate-releasing linkers 2011-11-13 2012-1-31
Modified polymers for delivery of polynucleotides, method of manufacture, and … 2011-3-28 2011-9-29
Conjugates Comprising a Biodegradable Polymer and Uses Therefor 2010-8-27 2011-2-24